Ok, so the way I read it is that it was a success for everyone over the age of 45.
But as a whole the study did not achieve the primary end point?
Viraleze™ reduced viral load in the full study population including all patient age groups (N=197), although the difference vs placebo was not statistically significant.
Ann: Viraleze shows antiviral efficacy in COVID-19 patients, page-3
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $41.20M | |||
| Open | High | Low | Value | Volume |
| 10.0¢ | 10.0¢ | 9.8¢ | $67.06K | 673.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 150305 | 9.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.0¢ | 21082 | 2 |
View Market Depth
| Last trade - 16.10pm 07/06/2024 (20 minute delay) ? |
|
|||||
|
Last
10.0¢ |
Change
0.000 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 10.0¢ | 10.5¢ | 9.8¢ | 355338 | ||
| Last updated 14.59pm 07/06/2024 ? | |||||
| SPL (ASX) Chart |